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ABSTRACT
Background. New-onset atrial fibrillation (AF) is the most common arrhythmia
in critically ill patients. Although evidence base and expert consensus opinion for
management have been summarised in several international guidelines, no specific
considerations for critically ill patients have been included. We aimed to establish
current practice of management of critically ill patients with new-onset AF.
Methods. We designed a short user-friendly online questionnaire. All members of the
Intensive Care Society were invited via email containing a link to the questionnaire,
which comprised 21 questions. The online survey was conducted between November
2016 and December 2016.
Results. The response rate was 397/3152 (12.6%). Themajority of respondents (81.1%)
worked inmixed Intensive Care Units and were consultants (71.8%).Most respondents
(39.5%) would start intervention on patients with fast new-onset AF and stable
blood pressure at a heart rate between 120 and 139 beats/min. However, 34.8% of
participants would treat all patients who developed new-onset fast AF. Amiodarone
and beta-blockers (80.9% and 11.6% of answers) were the most commonly used anti-
arrhythmics. A total of 63.8% of respondents do not regularly anti-coagulate critically
ill patients with new-onset fast AF, while 30.8% anti-coagulate within 72 hours. A total
of 68.0% of survey respondents do not routinely use stroke risk scores in critically ill
patients with new-onset AF. A total of 85.4% of participants would consider taking part
in a clinical trial investigating treatment of new-onset fast AF in the critically ill.
Discussion. Our results suggest a considerable disparity between contemporary practice
of management of new-onset AF in critical illness and treatment recommendations
for the general patient population suffering from AF, particularly with regard to anti-
arrhythmics and anti-coagulation used. Amongst intensivists, there is a substantial
interest in research for management of new-onset AF in critically ill patients.
Subjects Anaesthesiology and Pain Management, Cardiology, Emergency and Critical Care
Keywords Atrial fibrillation, Critical care, Sepsis, Arrhythmia, Anti-coagulation,
Anti-arrhythmics
How to cite this article Chean et al. (2017), Current practice in the management of new-onset atrial fibrillation in critically ill patients: a
UK-wide survey. PeerJ 5:e3716; DOI 10.7717/peerj.3716
INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia in both the general
population and the critical care setting (Makrygiannis et al., 2014; Seguin et al., 2004).
New-onset fast AF is defined as atrial fibrillation with a rapid ventricular response of more
than 100 beats per minute (bpm) in patients without a previous history of atrial fibrillation.
In the past decades there has been increased attention to new-onset AF in patients in
critical care, because it is associated with a worse prognosis (Chen et al., 2015; Shaver et
al., 2015). Evidence is growing that new-onset AF is associated with longer Intensive Care
Unit (ICU) stay and higher mortality (Reinelt et al., 2001; Tseng et al., 2016; Yoshida et al.,
2015). Observational studies suggested that the prevalence of AF in non-cardiac medical
ICUs ranges from 5 to 26% (Carrera et al., 2016; Chen et al., 2015), and affects up to 10%
of patients in surgical ICUs (Knotzer et al., 2000; Seguin et al., 2004).
However, despite the relatively high incidence of new-onset AF among critically ill
patients, there is paucity of evidence for its management in the critical care setting. In
particular, little is known about new-onset AF in comparison to pre-existing AF in this
subset of patients. Previous studies have mainly investigated the epidemiology, risk factors
and outcomes of new-onset atrial fibrillation in critical care, while little evidence, which is
mainly based on small single-centre studies, is available for treatment (Yoshida et al., 2015).
As a result, guidance on management of AF is based on the evidence obtained in the
general population and does not include patients in intensive care. We performed an
online survey amongst practising intensivists in the United Kingdom to establish current
practice regarding the management of critically ill patients developing new-onset AF. We
also aimed to identify areas in which adherence to current guidance is low and further
research is needed to clarify uncertainties in the treatment of these patients.
METHODS
We designed a short user-friendly online questionnaire using Qualtrics R© (Provo, UT,
USA) to assess the knowledge and to explore the current practice of British critical care
physicians in managing new-onset atrial fibrillation. The questionnaire was pilot-tested
and revised based on the question value. Where clinically relevant, more than one answer
could be given.
Selection sample
The survey population consisted of 3,152medical members of Intensive Care Society (ICS),
who are practicing intensive care doctors in the UK and for whom email contacts were
available. We excluded critical care doctors who did not practise or were retired.
The participants received an email containing the link to the questionnaire, which was
a web-based survey comprising of 21 questions and developed using the open source
survey application Qualtrics R©. The online survey was conducted from November 2016 to
December 2016.
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Questionnaire
The survey was anonymous and included a consent form at the beginning of the survey and
in the email circulated to all participants. The consent form explained the purpose of the
study, the risks and benefits and data management. The survey consisted of 21 questions,
which were divided into two domains. The first domain comprised seven questions, which
mainly recorded the background and demographic data of the responding physicians and
their critical care unit. The second domain had 14 questions that aimed to identify current
treatment strategies for critically ill patients with new-onset fast atrial fibrillation. The
survey took no more than 10 min to complete.
Demographic variables included type of practice hospitals (district general, tertiary
referral centre or university hospital), the number of patients admitted to the unit
per year, the number of staffed beds in the department, the case mix of the unit
department (predominantly surgical, medical, mixed or specialist ICU) as well as the
level of training, years of experience and any secondary specialty of the survey participants.
To identify and explore the current practice in managing critically ill patients with new-
onset AF, participants were asked to state a threshold heart rate at which they intervene
in patients with fast AF and stable blood pressure, whether they favour rhythm or rate
control as the primary treatment goal, the most commonly used anti-arrhythmic drugs
and the reasons for their choice. Survey participants were also asked about their treatment
strategy in an example of a critically ill patient with chest sepsis who developed new-onset
AF with a heart rate of 140–160 beats per minute. In this survey question, participants
were given options of different treatment strategies, including electrolyte supplementation,
Direct Current (DC) cardioversion and anti-arrhythmic drugs. Survey participants were
requested to state their target serum potassium and serum magnesium level among critical
care patients with new-onset AF.
Finally, participants were also asked about their anti-coagulation practice including
duration and medication used and their views on stroke risk assessments in critically ill
patients with new-onset AF. A further question explored the use of transoesophageal or
transthoracic echocardiography to guide treatment. At the end of the survey, their views
on conducting a clinical trial investigating treatment of new-onset AF in this subgroup of
patients were obtained. This included the anti-arrhythmic medications at highest priority
for investigation and acceptability of a placebo arm in a research study investigating the
effectiveness of anti-arrhythmics in critically ill patients with new-onset AF.
The full content of the survey is available as Supplemental Information 1.
Data analysis
A survey data report was auto-generated by Qualtrics R© to aid data analysis. Descriptive
statistics were carried out by providing absolute numbers and percentages of background
and demographic variables and for all questions relating to knowledge and current practice.
Where applicable, contingency tables were produced and analysed using Fisher’s exact test.
To measure of association between two nominal variables, Cramer’s V was used and
interpreted as follows: 0.1–0.29 weak association, 0.3–0.5 moderate association, >0.5
strong association.
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RESULTS
Demographics of survey participants
Questionnaires were sent to 3,152 members of the Intensive Care Society (ICS) who had
updated email addresses available. We received 427 responses. Survey links that had been
opened without provision of replies were excluded from the study. 397 complete survey
responses were obtained (12.6%). We excluded 30 surveys with incomplete answers on
the management of new-onset AF in critically ill patients from the analysis. Four lacked
information on background and demographics and were also excluded.
A total of 46.6% of respondents were from District General Hospitals; a smaller
proportion (38.5%) worked in University Hospitals or Tertiary referral centres. The
admission rate ranged between 500 and 2,000 patients/year in most centres, 81.1% of units
were mixed ICUs admitting medical and surgical patients (Table 1).
Most respondents (47.2%) worked on units with 11–20 staffed beds (level 2 and level
3). Our results indicate that mainly senior medical staff responded to the survey invitation,
with Consultants representing 71.8% of respondents; 53.9% had more than 10 years of
experience in Critical Care. Anaesthesia was the most common secondary specialty stated
(83.9%) (Table 2).
Anti-arrhythmic treatment of new-onset AF
A total of 39.5% of respondents would start intervention on patients with fast new-onset AF
and stable blood pressure at a heart rate between 120 and 139 beats/min. However, a similar
proportion of respondents (34.8%) would treat all patients who developed new-onset fast
AF, independent of their heart rate, even if the blood pressure remained stable. A total
of 54.7% of respondents stated that the primary treatment goal of new-onset AF among
ICU patients with stable BP without a known cardiac history was rate control, while 40.3%
of respondents aimed for rhythm control. We analysed whether choosing rate control
versus rhythm control as primary treatment goal influenced physicians’ views on heart
rate at which they would intervene (Table 2). Although a significantly higher percentage
(p< 0.001) of physicians who stated ‘‘Rhythm control’’ as their primary treatment goal
would intervene at any heart rate, the overall association between primary treatment goal
and heart rate requiring intervention was only moderate (Cramer’s V = 0.316).
Amiodarone was by far the most commonly used anti-arrhythmic for treatment of
new-onset AF in critically ill patients (80.9% of answers), followed by beta-blockade
(11.6%) (Fig. 1).
We wanted to explore the primary treatment strategy for a typical critically ill patient
using a case vignette of a patient with chest sepsis, who develops fast new-onset AF with a
heart rate of 140–160 bpm. The patient had no cardiac history, a blood pressure of 100/60
mmHg and received 0.25 mcg/kg/min noradrenaline. Most survey respondents opted
for electrolyte supplementation to high normal level and additional anti-arrhythmics
(53.6%). A total of 23.8% of respondents advocated electrolyte supplementation to a
high normal level only, and 14.9% opted for DC cardioversion when anti-arrhythmics
and electrolyte replacement fail to achieve rate and/or rhythm control. No one chose
to perform DC cardioversion only (Fig. 2). In critically ill patients with new-onset AF
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Table 1 Intensive Care Unit (ICU) characteristics and level of Level of training of survey respondents.
(A)
Which of the following answers most accurately describes
your hospital?
Response %
District General Hospital 185 46.60%
Teaching Hospital 59 14.86%
Tertiary Referral Centre or University Hospital 153 38.54%
Total 397 100.00%
(B)
Howmany patients are admitted to your Intensive Care
Unit per year?
Response %
<500 44 11.08%
500–1000 140 35.26%
1000–2000 129 32.49%
>2000 49 12.34%
I do not know 35 8.82%
Total 397 100.00%
(C)
Please state the case mix of your ICU/HDU: Response %
Predominantly surgical 19 4.79%
Predominantly medical 16 4.03%
Mixed ICU 322 81.11%
Specialist ICU (please name specialty): 40 10.08%
Total 397 100.00%
(D)
Please state your level of training: Response %
Consultant 285 71.79%
Trainee 94 23.68%
SAS 18 4.53%
Total 397 100.00%
(E)
Howmany years of experience do you have in Critical
Care?
Response %
<1 year 4 1.01%
1–3 years 42 10.58%
3–5 years 44 11.08%
5–10 years 93 23.43%
More than 10 years 214 53.90%
Total 397 100.00%
(continued on next page)
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Table 1 (continued)
(F)
Please state your complimentary specialty: Response %
Intensive Care Medicine only 37 9.32%
Anaesthesia 333 83.88%
Acute medicine 18 4.53%
Emergency Medicine 6 1.51%
Paediatrics 0 0.00%
Surgery 3 0.76%
Total 397 100.00%
Notes.
SAS, Specialty and associate specialist (Doctors not in training with at least four years postgraduate experience).
Table 2 Survey responses regarding heart rate at which doctors would intervene depending on their primary treatment goal (rate versus
rhythm control).
Rate control Rhythm control Total
Count 3 0 3
>160/beats per min
Percentage 1.5% 0.0% 0.9%
Count 30 17 47
100–119/beats per min
Percentage 15.2% 11.5% 13.6%
Count 93 48 141
120–139/beats per min
Percentage 47.0% 32.4% 40.8%
Count 30 9 39
140–159/beats per min
Percentage 15.2% 6.1% 11.3%
Count 42 74 116
At which heart rate would you
intervene in patients with fast AF
and stable blood pressure?
Independent of their heart rate I treat all
patients who have developed new onset fast
AF even if the blood pressure remains stable
Percentage 21.2% 50.0% 33.5%
Count 198 148 346
Total
Percentage 100.0% 100.0% 100.0%
74.3% of survey respondents aimed for serum Potassium level of >4.5 mmol/l and 59.7%
of survey respondents aimed for serum Magnesium level of 1.0–1.2 mmol/l (Fig. 3).
Pharmacodynamics properties and adverse effect profile were leading factors for choosing
anti-arrhythmic treatment for new-onset AF in critically ill patients (Fig. 4).
Anti-coagulation in patients with new-onset fast AF
A total of 63.8% of respondents stated that they would not regularly anti-coagulate
critically ill patients with new-onset fast AF, while 30.8% would anti-coagulate within
72 h (Table 3A). A total of 53.3% of all survey respondents thought that subcutaneous
low molecular weight heparin in therapeutic dose is appropriate for anti-coagulation and
26,8% considered intravenous highmolecular weight heparin as appropriate, provided that
no contra- indications for either substance were known (Table 3B). Sub-analysis excluding
respondents who gave ‘‘I do not regularly anti-coagulate critically ill patients with new
onset fast AF’’ as the only answer (136/362 respondents), revealed that either low or high
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Figure 1 Medications used for treatment of new-onset atrial fibrillation.
molecular weight heparin was considered appropriate for anti-coagulation by more than
98% of physicians.
A total of 68.0% of survey respondents did not use stroke risk scores routinely in critically
ill patients with new-onset AF to assess the need for anti-coagulation. A total of 30.9% of
survey respondents thought that stroke risk scores inaccurately reflect the risk of embolic
events in critically ill patients with new-onset atrial fibrillation due to prothrombotic
changes associated with critical illness. A total of 47.0% of respondents thought that
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Figure 2 Case vignette to assess treatment of new-onset atrial fibrillation with fast ventricular rate.
modified risk scores should be developed for critically ill patients with new-onset atrial
fibrillation (Table 4).
Approximately half of the respondents (52.2%) would request an echocardiogram in
patients with new-onset AF. Only a small minority (3.3%) would use transoesophageal
echocardiography, while a large proportion (48.9%) would request a transthoracic echocar-
diography. 39.2% of survey respondents did not routinely perform echocardiography to
guide treatment.
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		a)																		b)	
			 	
In	critically	ill	patients	with	new	onset	fast	AF,	
which	Serum	Potassium	level	would	you	aim	for?	 Response	 %	>3.5mmol/l	 3	 0.83%	>4	mmol/l	 82	 22.65%	>4.5	mmol/l	 269	 74.31%	>5	mmol/l	 7	 1.93%	I	do	not	aim	for	a	specific	serum	potassium	level	 1	 0.28%	Total	 362	 100.00%	
Figure 3 Electrolytes level targets in the management of atrial fibrillation. (continued on next page. . . )
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c)																							d)	
	
In	critically	ill	patients	with	new	onset	fast	AF,	
which	Serum	Magnesium	level	would	you	aim	for?	 Response	 %	
0.75-1	mmol/l	 30	 8.29%	
1.0-1.2	mmol/l	 216	 59.67%	
>1.2	mmol/l	 71	 19.61%	
I	do	not	aim	for	a	specific	serum	magnesium	level	 45	 12.43%	
Total	 362	 100.00%	
Figure 3 (. . .continued)
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Figure 4 Rationale for choosing anti-arrhythmic treatment for new-onset AF in critically ill patients.
Other reasons given included ‘‘Effectiveness’’, ‘‘Chance of cardioversion’’, ‘‘Amiodarone works’’.
Research interest amongst intensivists who treat patients with
new-onset AF
A total of 85.4% of survey respondents would consider taking part in a clinical trial
investigating treatment of new-onset fast AF in the critically ill. In the setting of a research
study on general ICU patients, amiodarone (74.0%) and beta-blockers (55.8%) were the
two most frequently mentioned pharmaceutical treatments to be investigated for critically
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Table 3 Survey responses regarding initiation of anti-coagulation treatment in atrial fibrillation and
choice of appropriate anticoagulants.
(A)
When would you normally anti-coagulate critically ill
patients with new-onset atrial fibrillation, if no contra-
indications for anti-coagulation are known?
Bar Response %
New onset AF within 24 h 26 7.18%
New onset AF within 48 h 54 14.92%
New onset AF within 72 h 35 9.67%
Before starting anti-arrhythmic medication 4 1.10%
After starting anti-arrhythmic medication 3 0.83%
Before DC cardioversion 9 2.49%
I do not regularly anti-coagulate critically ill patients with
new-onset fast AF
231 63.81%
Total 362 100.00%
(B)
In critically ill patients with new-onset fast atrial
fibrillation which of the following do you consider
appropriate for anti-coagulation provided that no contra-
indications are known? Please tick all answers that reflect
your views
Bar Response %
Intravenous High Molecular Weight heparin in
therapeutic dose
97 26.80%
Subcutaneous Low Molecular Weight heparin in
therapeutic dose
193 53.31%
Use of novel oral anti-coagulants (NOACs) 17 4.70%
Use of warfarin 20 5.52%
I do not regularly anti-coagulate critically ill patients with
new onset fast AF
190 52.49%
Total 517 100.00%
Table 4 Survey responses regarding stroke risk assessment in critically ill patients with new-onset atrial fibrillation.
Please tick all answers that reflect your views on stroke risk assess-
ment in critically ill patients with new-onset atrial fibrillation:
Bar Response %
I do not use stroke risk scores routinely in critically ill patients with
new onset AF to assess the need for anti-coagulation
246 67.96%
I regularly calculate a risk score (e.g., CHAD2, CHA2DS2-VASc) to
assess the need for anti-coagulation
39 10.77%
Stroke risk scores inaccurately reflect the risk of embolic events in
critically ill patients with new-onset atrial fibrillation due to pro-
thrombotic changes associated with critical illness
112 30.94%
Stroke risk scores favour anti-coagulation despite a higher risk of
bleeding in critical illness
73 20.17%
Modified risk scores should be developed for critically ill patients
with new-onset atrial fibrillation
170 46.96%
Total 640 100.00%
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ill patients with new-onset fast AF. There was a divided opinion regarding the use of a
placebo arm (i.e., not treating new-onset AF with anti-arrhythmics or rate-limiting agents,
when BP and cardiac output are stable). In the setting of a research study investigating
the effectiveness of anti-arrhythmic or rate-limiting agents in critically ill patients with
new-onset fast AF, 50.3% of respondents would not accept a placebo arm.
DISCUSSION
New-onset AF is the most commonly observed arrhythmia in critically ill patients
(Artucio & Pereira, 1990). It is associated with a worse prognosis (Champion et al., 2014;
Chen et al., 2015; Shaver et al., 2015) and longer ICU stays (Duby et al., 2017; Reinelt et al.,
2001), particularly in patients with sepsis, (Klein Klouwenberg et al., 2017). Despite the large
number of patients affected and potential long-term consequences (Walkey et al., 2014),
thorough research on treatment of new-onset AF is lacking (Walkey, Hogarth & Lip, 2015).
Our survey revealed two areas with substantial research need: Anti-arrhythmic treatment
of new-onset AF and anticoagulant therapy.
Prolonged periods of elevated heart rate are associated with a higher risk of cardiac
complications (Sander et al., 2005). A retrospective study in non-cardiac ICU patients
found that 37% of patients with new-onset AF suffered from hemodynamic instability
related to the development of AF (Kanji et al., 2012). Intensivists are concerned about
complications such as hypotension, myocardial ischemia and reduced organ perfusion,
all of which are known to be associated with new-onset AF with a high conduction rate.
In our survey, one third of intensivists would treat all patients with new-onset fast AF,
independent of their heart rate, even if the blood pressure remained stable, presumably
in an attempt to prevent these potentially harmful events. However, a slightly higher
proportion (39.5%) would set a heart rate of more than 120 bpm as a treatment threshold
in haemodynamically stable patients.
More than half of the intensivists who participated in our survey aimed for rate control
as the primary treatment goal, while about 40% prioritized rhythm control. A recent
single-center, retrospective, cohort study described a higher mortality in septic patients
with new-onset AF who failed to convert into sinus rhythm (Liu et al., 2016). Rhythm
control and rate control have both been used as outcome measures in the few therapeutic
studies available in the literature, although there is no clear guidance whether rate or
rhythm control is preferable to influence overall outcome of critical illness (Liu et al., 2016).
In fact, a recent systematic review on new-onset AF in non-cardiac critically ill patients
identified only five studies, which compared different treatment strategies for new-onset
AF in critically ill patients (Yoshida et al., 2015). However, only one of the studies was a ran-
domised controlled trial. Therapies studied to date include beta-blockers (Balser et al., 1998;
Meierhenrich et al., 2010), Vernakalant (Arrigo, Bettex & Rudiger, 2014), Diltiazem (Balser
et al., 1998), DC cardioversion (Arrigo et al., 2015; Kanji et al., 2012; Mayr et al., 2003;
Meierhenrich et al., 2010; Seguin et al., 2006), Amiodarone (Balser et al., 1998; Kanji et al.,
2012; Meierhenrich et al., 2010; Seguin et al., 2006; Sleeswijk et al., 2008), Sotalol (Kanji et
al., 2008) and digitalis glycosides (Meierhenrich et al., 2010; Seguin et al., 2006). The need
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to perform research on treatment of new-onset AF in critically ill patients is reflected
by the high percentage (85%) of intensivists who declared an interest in participating in
such research.
In our survey, amiodarone was the preferred pharmaceutical treatment for more
than 80% of intensivists who participated, potentially because it is associated with fewer
haemodynamic effects compared to beta-blockers and calcium channel blockers (Delle
Karth et al., 2001). Unfortunately, evidence supporting its use in critically ill patients is
limited to small single-centre studies only (Delle Karth et al., 2001; Shibata et al., 2016).
NICE guidelines recommend either a standard beta-blocker or a rate-limiting calcium-
channel blocker as initial monotherapy for patients with new-onset AF (Jones et al., 2014)
or, for patients who are sedentary, digoxin monotherapy. These guidelines have been
developed for patients with AF in the general population, but may not be transferable to
the intensive care setting due to different predisposing factors for AF in critically ill patients.
In particular, new-onset AF has been associated with inflammation and occurs in up to
46% of patients with septic shock (11). Patients with septic shock who developed new-onset
AF showed a continuous, significant increase in CRP plasma levels before occurrence of AF
(Meierhenrich et al., 2010). Further risk factors for new-onset AF in the critically ill include
inotropic support (Seguin et al., 2006), advanced age and high scores of severity of disease
(Yoshida et al., 2015). In the United Stated, where diltiazem is available for intravenous
administration, calcium-channel blockers were the most frequently used drugs to treat
new-onset AF during sepsis (Walkey et al., 2016), although the use of beta-blockers was
associated with improved mortality in a propensity analysis.
About a quarter of respondents would choose electrolyte supplementation to a high
normal level only, while more than half (53.6%) would add anti-arrhythmics or rate-
limiting agents as a primary treatment strategy. The use of intravenous magnesium
sulphate bolus application followed by continuous infusion achieved conversion to sinus
rhythm or decrease in heart rate <110 bpm in 16 of 29 patients (55%) in a small prospective
study (Sleeswijk et al., 2008), while magnesium-amiodarone step-up therapy achieved a
conversion rate of more than 90% within 24 h in a cohort of mixed critically ill patients.
Although these findings suggest that amiodarone, magnesium sulphate, or the combination
thereof might be effective to prevent or treat new-onset AF, more studies are needed to
evaluate the efficiency and safety profile of these drugs in the general critically ill population.
Haemodynamic stability during and immediately after the onset of AF and long-term
stroke risk are often dependent on underlying left ventricular systolic and diastolic function.
Echocardiography provides useful information on right and left ventricular function as well
as size of both atria to determine optimal treatment in patients with acute haemodynamic
deterioration. Although nearly half of the respondents would request a transthoracic echo,
a large proportion (39%) does not routinely use echocardiography to guide management
in this patient cohort.
NICE/ACC/AHA/ESC practice guidelines recommend routine anti-coagulation of
patients with new-onset AF depending on their individual risk of thromboembolic
events using established scores such as CHADS2 and CHA2DS2-VASc (Jones et al., 2014).
However, the risk of stroke and thromboembolic events in critically ill patients who
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develop new-onset AF has been evaluated in only very few studies. A recent prospective
observational study revealed that both CHADS2 and CHA2DS2-VASc are predictive of
thromboembolic events in the critical care setting (Champion et al., 2014), with a CHADS2
score of 4 or higher being themost accurate threshold. In a large retrospective study onmore
than 49,000 patients with sepsis, Walkey et al. (2011) described that new-onset AF during
severe sepsis was associated with a nearly four-fold increased risk of in-hospital ischemic
stroke, with threefold greater in-hospital stroke rates compared with patients without
AF during sepsis. Despite this adverse risk profile, 63.8% of intensivists participating
in our survey stated that they would not regularly anti-coagulate critically ill patients
with new-onset fast AF, while 30.8% of respondents would anti-coagulate within 72 h.
Intensivists may be reluctant to commence therapeutic anti-coagulation in critically ill
patients with new-onset AF because the risk/benefit ratio of anti-coagulation during acute
critical illness is often unclear. Critically ill patients may be at substantially increased risk
of severe bleeding due to thrombocytopenia, renal failure, liver failure, invasive devices,
and unscheduled procedures (Walkey, Hogarth & Lip, 2015), and bleeding complications
such as gastrointestinal haemorrhage or intracerebral bleeds are common (Darwish et al.,
2013). Currently recommended scores for stratification of thromboembolic risk, such as
the CHADS2 and CHA2DS2VASc scores, and the scores for hemorrhagic risk, like the
HAS-BLED score have limitations when applied in critically ill patients (Ferreira et al.,
2015). Hence scores developed to assess the stroke risk in the general population with AF,
are not routinely used by more than two thirds of intensivists who participated in our
survey. 30.9% of survey respondents felt that the currently recommended stroke risk scores
inaccurately reflect the risk of embolic events in critically ill patients with new-onset AF due
to prothrombotic changes associated with critical illness. Nearly half of the respondents
(47.0%) thought that modified risk scores should be developed for critically ill patients
with new-onset atrial fibrillation to take into account such alterations in the coagulation
system in critically ill patients. In an attempt to address this, a multi-centre observational
study has been set up to further identify clinical and echocardiographic risk factors for
thromboembolic events in critically ill patients with new-onset AF (Labbe et al., 2015).
Importantly, decisions to anti-coagulate patients with new-onset AF during critical
illness may influence the stroke risk beyond their critical care admission. More than half
of patients with new-onset AF have a later recurrence of AF (Walkey et al., 2014). Patients
with new-onset AF during acute illness also have an elevated long-term risk of stroke. A
proposed approach to long-termmanagement of patients who develop periods of AF during
critical illness includes re-assessment for rhythm and heart rate surveillance, cardiovascular
comorbidities, thyroid function, stroke risk and should include echocardiography and
patients’ preferences (Walkey, Hogarth & Lip, 2015) to manage stroke and cardiovascular
risk after ICU discharge. However, data are lacking to estimate rates of severe bleeding
versus stroke risk with use of systemic anti-coagulation during critical illness. Due to
this uncertainty, a recent review concluded that routine anti-coagulation for new-onset
AF among critically ill patients with elevated bleeding risk cannot be recommended as a
treatment where benefits outweigh risks (Walkey, Hogarth & Lip, 2015).
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Our survey has several limitations. We only approached members of the Intensive Care
Society (ICS), due the necessity of an accessible and up-to-date email distribution list.
Approximately two thirds of practising intensivists in the UK are members of the ICS,
indicating that a significant proportion of intensivists were not given the opportunity
to express their views. Given the low overall response rate, non-response bias may also
have influenced our results. However, acute care physicians are a professional group
with reportedly low survey response rates (Champion & Deye, 2017), likely due to time
constraints and high workload. This short online survey consisted of a limited number
of general questions only to allow rapid completion. Hence, we could not thoroughly
explore background knowledge and experience of the respondents in in this complex
field. In particular, treatment strategies in relation to cardiac function and combination
of therapies such as cardioversion in addition to anti-arrhythmic substances could not
be evaluated.
Our survey focused on general management of new-onset atrial fibrillation in critical
care; specific subgroups of patients including those after cardiothoracic surgery or with
primary cardiac diagnoses were not specifically addressed. These patient cohorts may
require separate investigations because of different pathomechanisms and treatment
requirements.
CONCLUSIONS
We identified a high variation in the use of anti-arrhythmic treatment in critically ill
patients with new-onset AF, which can be explained by the lack of both high-quality
studies and evidence to guide the management of new-onset AF in the critical care setting.
Intensivists expressed a substantial interest in research in this area, making it a priority
for future clinical trials. Interventional and observational studies will have to address the
benefits of pharmacotherapy for new-onset AF in critically ill patients and the effect of
individual drug choices on patient short and long-term outcomes. Further work is also
required to describe and assess the risk/benefit ratio of thromboembolic prophylaxis in
critically ill patients with new-onset AF.
ACKNOWLEDGEMENTS
We would like to thank Dr. Gary Masterson and Helle Sorensen for facilitating distribution
of the questionnaire and John Jones and Anna Ripley for providing data about ICS and
FICM membership. We would also like to thank all members of the Intensive Care Society
who took the time to respond to the survey invitation.
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
The authors received no funding for this work.
Competing Interests
The authors declare there are no competing interests.
Chean et al. (2017), PeerJ, DOI 10.7717/peerj.3716 16/20
Author Contributions
• Chung Shen Chean and Ingeborg Dorothea Welters conceived and designed
the experiments, performed the experiments, analyzed the data, contributed
reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables.
• Daniel McAuley conceived and designed the experiments, contributed reagents/materi-
als/analysis tools, reviewed drafts of the paper.
• Anthony Gordon contributed reagents/materials/analysis tools, reviewed drafts of the
paper.
Data Availability
The following information was supplied regarding data availability:
The raw data has been provided as a Supplementary File.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/
peerj.3716#supplemental-information.
REFERENCES
ArrigoM, Bettex D, Rudiger A. 2014.Management of atrial fibrillation in critically ill
patients. Critical Care Research and Practice 2014:840615 DOI 10.1155/2014/840615.
ArrigoM, Jaeger N, Seifert B, Spahn DR, Bettex D, Rudiger A. 2015. Disappointing suc-
cess of electrical cardioversion for new-onset atrial fibrillation in cardiosurgical ICU
patients. Critical Care Medicine 43:2354–2359
DOI 10.1097/CCM.0000000000001257.
Artucio H, Pereira M. 1990. Cardiac arrhythmias in critically ill patients: epidemiologic
study. Critical Care Medicine 18:1383–1388
DOI 10.1097/00003246-199012000-00015.
Balser JR, Martinez EA,Winters BD, Perdue PW, Clarke AW, HuangW, Tomaselli
GF, Dorman T, Campbell K, Lipsett P, BreslowMJ, Rosenfeld BA. 1998. Beta-
adrenergic blockade accelerates conversion of postoperative supraventricular tach-
yarrhythmias. Anesthesiology 89:1052–1059
DOI 10.1097/00000542-199811000-00004.
Carrera P, Thongprayoon C, CheungpasitpornW, Iyer VN, Moua T. 2016. Epidemiol-
ogy and outcome of new-onset atrial fibrillation in the medical intensive care unit.
Journal of Critical Care 36:102–106 DOI 10.1016/j.jcrc.2016.06.032f-005.
Champion S, Deye N. 2017.Management of cardiogenic shock: results from a sur-
vey in France and Belgium. Annales De Cardiologie Et D Angeiologie 66:59–65
DOI 10.1016/j.ancard.2016.10.013.
Champion S, Lefort Y, Gauzere BA, Drouet D, Bouchet BJ, Bossard G, Djouhri S,
Vandroux D, Mayaram K, Megarbane B. 2014. CHADS2 and CHA2DS2-
VASc scores can predict thromboembolic events after supraventricular ar-
rhythmia in the critically ill patients. Journal of Critical Care 29:854–858
DOI 10.1016/j.jcrc.2014.05.010.
Chean et al. (2017), PeerJ, DOI 10.7717/peerj.3716 17/20
Chen AY, Sokol SS, Kress JP, Lat I. 2015. New-onset atrial fibrillation is an independent
predictor of mortality in medical intensive care unit patients. The Annals of Pharma-
cotherapy 49:523–527 DOI 10.1177/1060028015574726.
Darwish OS, Strube S, Nguyen HM, Tanios MA. 2013. Challenges of anticoagulation
for atrial fibrillation in patients with severe sepsis. The Annals of Pharmacotherapy
47:1266–1271 DOI 10.1177/1060028013500938.
Delle Karth G, Geppert A, Neunteufl T, Priglinger U, HaumerM, Gschwandtner M,
Siostrzonek P, Heinz G. 2001. Amiodarone versus diltiazem for rate control in crit-
ically ill patients with atrial tachyarrhythmias. Critical Care Medicine 29:1149–1153
DOI 10.1097/00003246-200106000-00011.
Duby JJ, Heintz SJ, Bajorek SA, Heintz BH, Durbin-Johnson BP, Cocanour CS. 2017.
Prevalence and course of atrial fibrillation in critically ill trauma patients. Journal of
Intensive Care Medicine 32:140–145 DOI 10.1177/0885066615599150.
Ferreira C, Providencia R, Ferreira MJ, Goncalves LM. 2015. Atrial fibrillation and
non-cardiovascular diseases: a systematic review. Arquivos Brasileiros De Cardiologia
105:519–526 DOI 10.5935/abc.20150142.
Jones C, Pollit V, Fitzmaurice D, Cowan C, Guideline Development G. 2014. The
management of atrial fibrillation: summary of updated NICE guidance. BMJ
348:g3655 DOI 10.1136/bmj.g3655.
Kanji S, Stewart R, Fergusson DA, McIntyre L, Turgeon AF, Hebert PC. 2008. Treat-
ment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a sys-
tematic review of randomized controlled trials. Critical Care Medicine 36:1620–1624
DOI 10.1097/CCM.0b013e3181709e43.
Kanji S, Williamson DR, Yaghchi BM, Albert M, McIntyre L, Canadian Critical Care
Trials G. 2012. Epidemiology and management of atrial fibrillation in medical
and noncardiac surgical adult intensive care unit patients. Journal of Critical Care
27:326 e321–e328 DOI 10.1016/j.jcrc.2011.10.011.
Klein Klouwenberg PM, Frencken JF, Kuipers S, Ong DS, Peelen LM, Van Vught LA,
Schultz MJ, Van der Poll T, BontenMJ, Cremer OL, MARS Consortium. 2017.
Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill
patients with sepsis. A cohort study. American Journal of Respiratory and Critical Care
Medicine 195:205–211 DOI 10.1164/rccm.201603-0618OC.
Knotzer H, Mayr A, Ulmer H, LedererW, SchobersbergerW,Mutz N, HasibederW.
2000. Tachyarrhythmias in a surgical intensive care unit: a case-controlled epidemio-
logic study. Intensive Care Medicine 26:908–914 DOI 10.1007/s001340051280.
Labbe V, Ederhy S, FartoukhM, Cohen A. 2015. Should we administrate anticoagulants
to critically ill patients with new onset supraventricular arrhythmias? Archives of
Cardiovascular Diseases 108:217–219 DOI 10.1016/j.acvd.2015.01.001.
LiuWC, LinWY, Lin CS, Huang HB, Lin TC, Cheng SM, Yang SP, Lin JC, LinWS.
2016. Prognostic impact of restored sinus rhythm in patients with sepsis and new-
onset atrial fibrillation. Critical Care 20:373 DOI 10.1186/s13054-016-1548-2.
Makrygiannis SS, Margariti A, Rizikou D, Lampakis M, Vangelis S, Ampartzidou OS,
Katsifa K, Tselioti P, Foussas SG, Prekates AA. 2014. Incidence and predictors of
Chean et al. (2017), PeerJ, DOI 10.7717/peerj.3716 18/20
new-onset atrial fibrillation in noncardiac intensive care unit patients. Journal of
Critical Care 29:697.e1–697.e5 DOI 10.1016/j.jcrc.2014.03.029.
Mayr A, Ritsch N, Knotzer H, Dunser M, SchobersbergerW, Ulmer H, Mutz N,
HasibederW. 2003. Effectiveness of direct-current cardioversion for treatment
of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical
intensive care patients. Critical Care Medicine 31:401–405
DOI 10.1097/01.CCM.0000048627.39686.79.
Meierhenrich R, Steinhilber E, Eggermann C,Weiss M, Voglic S, Bogelein D, Gauss A,
Georgieff M, StahlW. 2010. Incidence and prognostic impact of new-onset atrial
fibrillation in patients with septic shock: a prospective observational study. Critical
Care 14:R108 DOI 10.1186/cc9057.
Reinelt P, Karth GD, Geppert A, Heinz G. 2001. Incidence and type of cardiac arrhyth-
mias in critically ill patients: a single center experience in a medical-cardiological
ICU. Intensive Care Medicine 27:1466–1473.
Sander O,Welters ID, Foex P, Sear JW. 2005. Impact of prolonged elevated heart rate on
incidence of major cardiac events in critically ill patients with a high risk of cardiac
complications. Critical Care Medicine 33:81–88
DOI 10.1097/01.CCM.0000150028.64264.14.
Seguin P, Laviolle B, Maurice A, Leclercq C, Malledant Y. 2006. Atrial fibrillation
in trauma patients requiring intensive care. Intensive Care Medicine 32:398–404
DOI 10.1007/s00134-005-0032-2.
Seguin P, Signouret T, Laviolle B, Branger B, Mallédant Y. 2004. Incidence and risk
factors of atrial fibrillation in a surgical intensive care unit*. Critical Care Medicine
32:722–726 DOI 10.1097/01.ccm.0000114579.56430.e0.
Shaver CM, ChenW, Janz DR, May AK, Darbar D, Bernard GR, Bastarache JA,Ware
LB. 2015. Atrial fibrillation is an independent predictor of mortality in critically ill
patients. Critical Care Medicine 43:2104–2111
DOI 10.1097/CCM.0000000000001166.
Shibata SC, Uchiyama A, Ohta N, Fujino Y. 2016. Efficacy and safety of landiolol
compared to amiodarone for the management of postoperative atrial fibrillation in
intensive care patients. Journal of Cardiothoracic and Vascular Anesthesia 30:418–422
DOI 10.1053/j.jvca.2015.09.007.
Sleeswijk ME, Tulleken JE, Van Noord T, Meertens JH, Ligtenberg JJ, Zijlstra JG. 2008.
Efficacy of magnesium-amiodarone step-up scheme in critically ill patients with
new-onset atrial fibrillation: a prospective observational study. Journal of Intensive
Care Medicine 23:61–66 DOI 10.1177/0885066607310181.
Tseng YH, Ko HK, Tseng YC, Lin YH, Kou YR. 2016. Atrial fibrillation on intensive care
unit admission independently increases the risk of weaning failure in nonheart fail-
ure mechanically ventilated patients in a medical intensive care unit: a retrospective
case-control study.Medicine 95:e3744 DOI 10.1097/MD.0000000000003744.
Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. 2014. Long-term outcomes following
development of new-onset atrial fibrillation during sepsis. Chest 146:1187–1195
DOI 10.1378/chest.14-0003.
Chean et al. (2017), PeerJ, DOI 10.7717/peerj.3716 19/20
Walkey AJ, Hogarth DK, Lip GY. 2015. Optimizing atrial fibrillation management: from
ICU and beyond. Chest 148:859–864 DOI 10.1378/chest.15-0358.
Walkey AJ, Quinn EK,Winter MR, McManus DD, Benjamin EJ. 2016. Prac-
tice patterns and outcomes associated with use of anticoagulation among
patients with atrial fibrillation during sepsis. JAMA Cardiology 1:682–690
DOI 10.1001/jamacardio.2016.2181.
Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. 2011. Incident stroke
and mortality associated with new-onset atrial fibrillation in patients hospitalized
with severe sepsis. Journal of the American Medical Association 306:2248–2254
DOI 10.1001/jama.2011.1615.
Yoshida T, Fujii T, Uchino S, TakinamiM. 2015. Epidemiology, prevention, and
treatment of new-onset atrial fibrillation in critically ill: a systematic review. Journal
of Intensive Care 3:19 DOI 10.1186/s40560-015-0085-4.
Chean et al. (2017), PeerJ, DOI 10.7717/peerj.3716 20/20
